永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

已收盘 02-02 16:08:05

2.570

-0.020

-0.77%

最高2.580	最低2.520	成交量5.00万
今开2.580	昨收2.590	日振幅2.32%
总市值15.88亿	流通市值15.88亿	总股本6.18亿
成交额12.76万	换手率0.01%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":2.57,"timestamp":1770019685004,"preClose":2.59,"halted":0,"volume":50005,"delay":0,"changeRate":-0.007722007722007729,"floatShares":618000000,"shares":618000000,"eps":-0.363229,"marketStatus":"已收盘","change":-0.02,"latestTime":"02-02 16:08:05","open":2.58,"high":2.58,"low":2.52,"amount":127612,"amplitude":0.023166,"askPrice":2.6,"askSize":20000,"bidPrice":2.52,"bidSize":4000,"shortable":0,"etf":0,"ttmEps":-0.397,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770082200000},"marketStatusCode":5,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":2.59,"openAndCloseTimeList":[[1769995800000,1770004800000],[1770008400000,1770019200000]],"volumeRatio":0.11274,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2608386599","title":"润都股份(002923.SZ)：目前有1类创新药(化学药)盐酸去甲乌药碱注射液 药品能否获批上市等存在不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2608386599","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608386599?lang=zh_cn&edition=full","pubTime":"2026-02-02 19:56","pubTimestamp":1770033385,"startTime":"0","endTime":"0","summary":"智通财经APP讯，润都股份(002923.SZ)发布股价异动公告称，公司目前有1类创新药(化学药)盐酸去甲乌药碱注射液(规格：2ml:2.5mg)及其原料药，其药品审评工作正在有序进行。创新药具有研发周期长，投入大，风险高的特点，药品能否获批上市以及获批上市的时间、上市后的生产和销售情况存在不确定性，短期内也不会对公司业绩产生重大影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400706.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK0239","BK1574","002923","BK1161","06978"],"gpt_icon":0},{"id":"1184642537","title":"永泰生物（06978）1月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1184642537","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184642537?lang=zh_cn&edition=full","pubTime":"2026-02-02 17:25","pubTimestamp":1770024358,"startTime":"0","endTime":"0","summary":"2026年2月2日，永泰生物製藥有限公司发布截至2026年1月31日的股份变动月报表。报告显示，公司法定/注册股本仍为5,000,000,000股，面值每股USD 0.001，总额维持USD 5,000,000，较上月无变动。公司已发行股份合计617,500,800股，当月无新增发行、购回或注销行为，库藏股数量也保持为零。报告期内无新转换行为。截至1月底，公司股本与股数维持稳定。董事谭錚于公告中确认，公司在报告期内遵守了香港联交所《上市规则》及相关法律规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978"],"gpt_icon":0},{"id":"2608836458","title":"招商证券国际：重申石药集团(01093)“中性”评级 中国创新药进入全球管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2608836458","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608836458?lang=zh_cn&edition=full","pubTime":"2026-02-02 10:50","pubTimestamp":1770000610,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招商证券国际发布研报称，石药集团与阿斯利康达成历史性交易公告，表示看好交易，但需等待石药或阿斯利康披露更多长效GLP-1全球开发细节。重申“中性”评级，认为短期基本面仍存隐忧。该行表示，根据石药最新公告，与阿斯利康合作的关键临床候选药物为SYH2082，长效GLP-1R/GIPR双激动剂，现已进入I期临床。该行认为siRNA进入肥胖维持市场，将对所有胜肽类方案构成真正威胁。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","06099","06978","01093"],"gpt_icon":0},{"id":"2608888327","title":"医药生物行业跟踪周报：降息等多因素支持科研上游持续复苏 重点推荐皓元医药、奥浦迈等","url":"https://stock-news.laohu8.com/highlight/detail?id=2608888327","media":"东吴证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608888327?lang=zh_cn&edition=full","pubTime":"2026-02-01 00:00","pubTimestamp":1769875200,"startTime":"0","endTime":"0","summary":"建议关注皓元医药、百奥赛图、百普赛斯、奥浦迈、药康生物、纳微科技和阿拉丁等。从小核酸角度，建议关注前沿生物、福元医药、悦康药业等。从GLP1 角度，建议关注联邦制药、博瑞医药、众生药业、信达生物等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260201204647a46f7473&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260201204647a46f7473&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03933","BK1574","BK1191","06978","BK1161","09606"],"gpt_icon":0},{"id":"2608000504","title":"中英经贸合作新范本：阿斯利康千亿投资引领跨国药企在华发展步伐","url":"https://stock-news.laohu8.com/highlight/detail?id=2608000504","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608000504?lang=zh_cn&edition=full","pubTime":"2026-01-31 18:12","pubTimestamp":1769854377,"startTime":"0","endTime":"0","summary":"2026年1月29日，北京寒意未消，却迎来一场暖意融融的产业盛事——阿斯利康宣布，计划于2030年前在中国投资逾1000亿元人民币，以扩大在药品生产与研发领域的布局。这是阿斯利康自1993年入华33年来最大规模的战略投资。这一数字不仅刷新了跨国药企在华单笔投资纪录，更以全产业链覆盖的深度与广度，成为跨国药企在华战略布局和中国医药产业开放与创新的生动注脚。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260131181357a6c33f49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260131181357a6c33f49&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0501845795.SGD","01093","BK1515","BK1191","LU0140636845.USD","IE00B543WZ88.USD","IE0008369823.USD","LU1328277881.USD","IE00BZ08YR35.GBP","LU0315179316.USD","IE0008368742.USD","LU1813983027.USD","LU1960683339.HKD","LU1226287529.USD","LU0314109678.HKD","LU1993786604.SGD","LU0067412154.USD","IE00B5MMRT66.SGD","LU1008478684.HKD","LU1152091168.USD","LU0880133367.SGD","SG9999004220.SGD","06978","LU1226287875.USD","BK1574","BK1161","LU1951186391.HKD","LU0072913022.USD","IE00BZ08YS42.EUR","LU1807302812.USD","HK0000165453.HKD","LU1226287792.SGD","IE00B031HY20.USD","LU1152091754.HKD","LU0326950275.SGD","LU1226288170.HKD","LU1226288253.USD","BK1521","LU2039709279.SGD","IE00BZ08YT58.USD"],"gpt_icon":0},{"id":"2607022227","title":"【ETF动向】1月30日华宝恒生港股通创新药精选ETF基金跌2.45%，份额增加1.2亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2607022227","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607022227?lang=zh_cn&edition=full","pubTime":"2026-01-31 06:32","pubTimestamp":1769812326,"startTime":"0","endTime":"0","summary":"证券之星消息，1月30日，华宝恒生港股通创新药精选ETF基金（520880）跌2.45%，成交额3.88亿元。当日份额增加了1.2亿份，最新份额为47.28亿份，近20个交易日份额增加5.28亿份。当日资金净流入16.12万元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为24.57亿元。华宝恒生港股通创新药精选ETF基金跟踪标的为恒生港股通创新药精选指数，成立（2025-06-27）以来超额回报为-3.88%，近一个月超额回报为-0.72%，管理人为华宝基金公司，基金经理为丰晨成。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013100004232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","06978","159992","BK1161"],"gpt_icon":0},{"id":"2607025069","title":"10倍创新药大牛股，突曝预亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2607025069","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607025069?lang=zh_cn&edition=full","pubTime":"2026-01-30 23:28","pubTimestamp":1769786880,"startTime":"0","endTime":"0","summary":"百利天恒预计，2025年将亏损11亿元中国基金报记者 卢鸰在2024年大赚37亿元之后，10倍创新药牛股百利天恒预计2025年将亏损11亿元。2025年10月21日，百利天恒通过港交所上市委员会聆讯；2025年11月12日，百利天恒公告延迟港股上市计划。截至2026年1月30日，百利天恒尚未宣布重启港股上市计划。1月30日，百利天恒股价以277.75元/股报收，最新市值为1147亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":null,"url":"http://mp.weixin.qq.com/s?__biz=MzA5MDEzNjQwMA==&mid=2656345367&idx=1&sn=6d9f3a7d0ab603a9f03f2194fc189462&chksm=8ad84b2e76fdccc0479715eb16190a737f4b62dedddd6a30fe4fb9547e6c3d023de9f78114f9&scene=0#rd","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MDEzNjQwMA==&mid=2656345367&idx=1&sn=6d9f3a7d0ab603a9f03f2194fc189462&chksm=8ad84b2e76fdccc0479715eb16190a737f4b62dedddd6a30fe4fb9547e6c3d023de9f78114f9&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","159992","06978"],"gpt_icon":0},{"id":"2607014721","title":"康哲药业(00867)：创新药补体因子B抑制剂CMS-D017 获得阵发性睡眠性血红蛋白尿症适应症药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2607014721","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607014721?lang=zh_cn&edition=full","pubTime":"2026-01-30 19:25","pubTimestamp":1769772345,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 公布，于2026年1月30日，集团自主研发的创新药CMS-D017胶囊获得中国国家药品监督管理局签发的药物临床试验批准通知书。NMPA同意集团在中国健康参与者中开展评价CMS-D017安全性、耐受性、药代动力学和药效动力学特征的临床试验。CMS-D017是一种新型选择性补体因子B小分子抑制剂。CMS-D017在临床前研究中表现出优异的有效性和安全性，临床拟用于治疗阵发性睡眠性血红蛋白尿症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BYV24P56.USD","LU0661504455.SGD","00867","BK1574","SG9999015952.SGD","LU1894683264.USD","BK4588","LU1003077747.HKD","LU2488822045.USD","LU2500361329.USD","IE00BVYPNP33.GBP","LU0949170772.SGD","06978","BK1191","LU0545039389.USD","LU2637428348.USD","IE00BVYPNQ40.USD","IE00BMCWC346.EUR","LU0738911758.USD","SG9999015978.USD","BK1161","LU2346227817.USD","SG9999004220.SGD","159992","LU0553294199.USD","SG9999015986.USD","BK4208","BK4585","IE00BGHQDM52.EUR","SG9999015945.SGD","CMS","LU1894683348.USD","BK1593"],"gpt_icon":0},{"id":"2607610067","title":"康哲药业(00867)：创新药磷酸芦可替尼乳膏中国上市许可申请获批为中国批准的首款且唯一用于白癜风治疗的靶向药","url":"https://stock-news.laohu8.com/highlight/detail?id=2607610067","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607610067?lang=zh_cn&edition=full","pubTime":"2026-01-30 12:14","pubTimestamp":1769746492,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业(00867)发布公告，旗下德镁医药有限公司(“德镁医药”，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市，)已于2026年1月30日获得中国国家药品监督管理局(NMPA)批准磷酸芦可替尼乳膏(白癜风适应症)新药上市许可申请(NDA)。产品用于治疗12岁及以上儿童和成人患者伴面部受累的非节段型白癜风，是中国批准的首款且唯一用于白癜风治疗的靶向药，满足巨大未被满足的临床需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399625.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999015978.USD","BK1593","SG9999015952.SGD","IE00BMCWC346.EUR","BK1191","SG9999004220.SGD","159992","IE00BVYPNQ40.USD","LU2488822045.USD","BK1161","00867","IE00BVYPNP33.GBP","IE00BGHQDM52.EUR","SG9999015945.SGD","SG9999015986.USD","IE00BYV24P56.USD","BK1574","06978"],"gpt_icon":0},{"id":"2607092682","title":"国产创新药BD交易呈现井喷式增长，2026年1月持续爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=2607092682","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607092682?lang=zh_cn&edition=full","pubTime":"2026-01-30 11:51","pubTimestamp":1769745089,"startTime":"0","endTime":"0","summary":"近年来，国产创新药BD交易呈现井喷式增长，不少创新药扬帆出海，在国际舞台打开市场空间。数据显示，2025年中国创新药BD出海授权交易总金额达到1,356.55亿美元，交易总数达157起。本次交易总额最高可达10.58亿欧元。2025年8月，荣昌生物发布消息称，RC148用于晚期恶性实体肿瘤Ⅱ期的临床试验申请已获FDA批准。2026年1月国产创新药BD出海的密集突破，既是2025年爆发式增长态势的延续，也是中国创新药产业高质量发展的生动缩影。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130115551a4675992&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130115551a4675992&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU2328871848.SGD","BK1583","LU1969619763.USD","06978","BK1574","09995"],"gpt_icon":0},{"id":"2607806521","title":"成都先导与康哲药业达成合作 DEL及HAILO平台赋能多靶点创新药开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2607806521","media":"人民财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607806521?lang=zh_cn&edition=full","pubTime":"2026-01-30 09:13","pubTimestamp":1769735597,"startTime":"0","endTime":"0","summary":"人民财讯1月30日电，据成都先导消息，近日，成都先导与康哲药业控股有限公司（简称“康哲药业”）附属公司签署合作协议，成都先导将为康哲药业针对多个特定靶点的创新药物提供开发服务。成都先导将依托DNA编码化合物库（DEL）技术平台及高通量AI驱动分子优化平台HAILO，为康哲药业提供从靶点验证到临床前候选化合物（PCC）的一站式开发服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303636273434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","SG9999015978.USD","BK1191","IE00BGHQDM52.EUR","SG9999004220.SGD","LU2488822045.USD","IE00BVYPNQ40.USD","IE00BMCWC346.EUR","BK0216","00867","SG9999015952.SGD","SG9999015945.SGD","159992","688222","BK1593","BK1574","SG9999015986.USD","BK1161","IE00BYV24P56.USD","IE00BVYPNP33.GBP"],"gpt_icon":0},{"id":"2607052151","title":"【ETF动向】1月29日广发中证创新药产业ETF基金涨0.47%，份额增加2.13亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2607052151","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607052151?lang=zh_cn&edition=full","pubTime":"2026-01-30 06:31","pubTimestamp":1769725902,"startTime":"0","endTime":"0","summary":"证券之星消息，1月29日，广发中证创新药产业ETF基金（515120）涨0.47%，成交额4.1亿元。当日份额增加了2.13亿份，最新份额为141.11亿份，近20个交易日份额增加26.97亿份。当日资金净流入1.64亿元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为89.45亿元。广发中证创新药产业ETF基金跟踪标的为中证创新药产业指数，成立（2020-12-03）以来超额回报为-1.81%，近一个月超额回报为-0.03%，管理人为广发基金公司，基金经理为罗国庆。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000004914.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","06978","159992","BK1161"],"gpt_icon":0},{"id":"2607024507","title":"恒瑞医药(01276)创新药注射用卡瑞利珠单抗联合甲磺酸阿帕替尼片新适应症的上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2607024507","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607024507?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:17","pubTimestamp":1769678270,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，公司及子公司苏州盛迪亚生物医药有限公司收到国家药品监督管理局下发的《受理通知书》，公司创新药注射用卡瑞利珠单抗联合甲磺酸阿帕替尼片新适应症的上市许可申请获受理。研究期中分析结果表明，与单纯 TACE 治疗相比，卡瑞利珠单抗联合甲磺酸阿帕替尼和 TACE 组 BIRC 评估的 PFS 达到了显著有临床意义的改善，且已观察到 OS 获益趋势。该联合疗法有望成为不可切除肝细胞癌患者的临床治疗新选择。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","159992","BK0239","LU1997245094.SGD","BK0060","LU1023057109.AUD","LU0359201612.USD","BK1191","06978","LU2097828631.EUR","600276","LU1328615791.USD","LU1064131003.USD","LU2580892789.USD","BK1574","LU1064130708.USD","LU2328871848.SGD","LU1655091616.SGD","BK0183","LU2488822045.USD","LU2097828805.USD","LU1146622755.USD","BK1161","LU2097828557.USD","LU2543165471.USD","LU2289578879.USD","BK0012","LU1580142542.USD","LU0359202008.SGD","LU1997244956.HKD","LU2495084118.USD","01276","LU2097828714.EUR","LU0405327148.USD","LU1969619763.USD","LU0359201885.HKD","LU1997245177.USD","LU1781817850.SGD","LU2148510915.USD","BK0028","BK0196","LU1820825898.SGD","LU2580892862.HKD","LU0405327494.USD","LU2097828474.EUR","LU1255011170.USD"],"gpt_icon":0},{"id":"2607272710","title":"广生堂：管理层聚焦高质量推进创新药临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2607272710","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607272710?lang=zh_cn&edition=full","pubTime":"2026-01-29 09:06","pubTimestamp":1769648767,"startTime":"0","endTime":"0","summary":"证券之星消息，广生堂01月28日在投资者关系平台上答复投资者关心的问题。市值受多重因素影响，包括但不限于研发进展、监管审批结果、企业经营业绩、资本市环境、行业政策及宏观经济等，且创新药研发周期长、投入大、风险高，敬请投资者注意投资风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900007004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1574","BK1161","BK0239","159992","300436"],"gpt_icon":0},{"id":"2607777039","title":"创新药DeepSeek模式，过时了","url":"https://stock-news.laohu8.com/highlight/detail?id=2607777039","media":"阿基米德Biotech","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607777039?lang=zh_cn&edition=full","pubTime":"2026-01-28 21:15","pubTimestamp":1769606100,"startTime":"0","endTime":"0","summary":"中国创新药高效率低成本的DeepSeek模式，也即以恒瑞医药为代表的Fast-Follow模式，正面临边际效用递减，直至完全失效。在自免领域，Dupixent长期统治AD药物市场，并将适应症拓展至2型炎症相关疾病的全谱系，其销售额2025前三季度突破131亿美元，预计2026年销售额198亿美元。Dupixent被蛋白降解剂掀了牌桌。单药治疗8周，实现经安慰剂校正后内脏脂肪减少14.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128213349a460a278&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128213349a460a278&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978"],"gpt_icon":0},{"id":"2606979167","title":"中国上市、全球首发！百济神州这一创新药开启血液肿瘤治疗新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=2606979167","media":"上观新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606979167?lang=zh_cn&edition=full","pubTime":"2026-01-28 17:17","pubTimestamp":1769591825,"startTime":"0","endTime":"0","summary":"百济神州新型BCL2抑制剂索托克拉（百悦达）中国上市会暨全球首发盛典日前举行。会上，众多专家共同就国内慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）以及套细胞淋巴瘤（MCL）的诊疗现状、治疗策略及创新诊疗格局展开分享与讨论，以期推动创新药物更好地造福国内患者。近年来，我国血液肿瘤的防治依然面临严峻挑战。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601283633690762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ONC","BK1574","BK4526","BK0239","LU1251922891.USD","06078","BK1209","LU0588546209.SGD","LU0329678337.USD","LU1719994722.HKD","06978","BK1583","LU1770034418.SGD","159992","BK1500","BK4139","LU2328871848.SGD","BK1161","688235","LU0329678170.USD","LU1969619763.USD","BK4585","LU2488822045.USD","LU1303224171.USD","LU0307460666.USD","LU0737861772.HKD","BK1588","06160"],"gpt_icon":0},{"id":"2606479614","title":"中国创新药大时代或还没有结束","url":"https://stock-news.laohu8.com/highlight/detail?id=2606479614","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606479614?lang=zh_cn&edition=full","pubTime":"2026-01-28 16:41","pubTimestamp":1769589681,"startTime":"0","endTime":"0","summary":"去年五月，三生制药与辉瑞创纪录的BD协议，如同一道惊雷，正式拉开了创新药行情的序幕。创新药的大时代，可能仍在曲折中酝酿其新的篇章。中国创新药企展现出的“高性价比”研发能力，已成为全球医药产业链中难以替代的一环。中国生物制药披露的TYK2抑制剂在溃疡性结肠炎领域的亮眼数据，同样使其在自身免疫疾病这个巨大市场中占据了有利位置。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026012800027722.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","06978","159992"],"gpt_icon":0},{"id":"2607721192","title":"肿瘤创新药企先声再明IPO闯关：对赌压顶，近三年亏损超11亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2607721192","media":"Ofweek光电信息网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607721192?lang=zh_cn&edition=full","pubTime":"2026-01-28 09:15","pubTimestamp":1769562900,"startTime":"0","endTime":"0","summary":"2026年1月9日，先声药业旗下肿瘤创新药子公司先声再明正式向港交所递交招股书。招股书显示，截至2025年11月30日，公司存在超11亿元的赎回负债。2024年恩立妥获批完善消化道肿瘤管线，先声再明于2025年先后与艾伯维、Ipsen及NextCure达成多项对外许可合作，潜在总交易价值合计超过28亿美元，最终在2026年初递交招股书，冲刺港股上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128092810a45e0799&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128092810a45e0799&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02096","BK1191","BK1574","BK1583","BK1161","06978"],"gpt_icon":0},{"id":"2606751452","title":"【ETF动向】1月27日银华中证创新药产业ETF基金跌1.61%，份额增加2.49亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2606751452","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606751452?lang=zh_cn&edition=full","pubTime":"2026-01-28 08:05","pubTimestamp":1769558727,"startTime":"0","endTime":"0","summary":"证券之星消息，1月27日，银华中证创新药产业ETF基金（159992）跌1.61%，成交额7.62亿元。当日份额增加了2.49亿份，最新份额为177.74亿份，近20个交易日份额增加27.44亿份。当日资金净流入1097.96万元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为151.7亿元。银华中证创新药产业ETF基金跟踪标的为中证创新药产业指数，成立（2020-03-20）以来超额回报为-7.68%，近一个月超额回报为0.06%，管理人为银华基金公司，基金经理为马君 王帅。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800006689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1574","06978","BK1161"],"gpt_icon":0},{"id":"2606786225","title":"永泰生物-B拟向天士力提供细胞治疗处理服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2606786225","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606786225?lang=zh_cn&edition=full","pubTime":"2026-01-27 19:15","pubTimestamp":1769512549,"startTime":"0","endTime":"0","summary":"格隆汇1月27日丨永泰生物-B(06978.HK)公告，于2026年1月27日，公司间接非全资附属公司永泰北京与天士力订立委托服务协议，据此，永泰北京同意就项目向天士力提供特定细胞产品解冻、洗涤、配方、灌装、检测及相关技术与项目管理服务。根据委托服务协议，天士力应向永泰北京支付总额为人民币975万元(含税)的服务费，该金额将根据实际临床样本批次数量及实际服务期进行调整，服务期自委托服务协议生效日期起计约24个月。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127191611a45bddaa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127191611a45bddaa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","06978"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":0.0571},{"period":"1month","weight":-0.116},{"period":"3month","weight":-0.1725},{"period":"6month","weight":-0.3525},{"period":"1year","weight":-0.0547},{"period":"ytd","weight":-0.116}],"compareEarnings":[{"period":"1week","weight":0.0238},{"period":"1month","weight":0.0685},{"period":"3month","weight":0.0571},{"period":"6month","weight":0.1175},{"period":"1year","weight":0.3541},{"period":"ytd","weight":0.0685}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074078},{"month":2,"riseRate":0.6,"avgChangeRate":0.206387},{"month":3,"riseRate":0.4,"avgChangeRate":-0.092735},{"month":4,"riseRate":0.2,"avgChangeRate":-0.078794},{"month":5,"riseRate":0.4,"avgChangeRate":-0.038349},{"month":6,"riseRate":0.8,"avgChangeRate":0.080731},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000149},{"month":8,"riseRate":0.5,"avgChangeRate":0.012587},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}